Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 7
Submit an article Journal homepage
507
Views
4
CrossRef citations to date
0
Altmetric
Letter to the Editor

Current lipid-modifying agents

Aris P AgouridisUniversity of Ioannina, Medical School, Department of Internal Medicine, 45110 Ioannina, Greece;Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free London Foundation Trust, Pond Street, London, NW3 2QG, UK+44 20 7830 2258; +44 20 7830 2235; [email protected]
(Honorary Clinical Research Fellow) ,
Theodosios D FilippatosUniversity of Ioannina, Medical School, Department of Internal Medicine, 45110 Ioannina, Greece
&
Niki KatsikiAristotle University of Thessaloniki, Hippokration Hospital, Second Propedeutic Department of Internal Medicine, Medical School, Thessaloniki, Greece
Pages 1117-1118 | Published online: 06 Apr 2015

Bibliography

  • Pisaniello AD, Scherer DJ, Kataoka Y, et al. Ongoing challenges for pharmacotherapy for dyslipidemia. Expert Opin Pharmacother 2015;16:347-56
  • Tziomalos K, Karagiannis A, Mikhailidis DP, et al. Colesevelam: a new and improved bile acid sequestrant? Curr Pharm Des 2013;19:3115-23
  • Doggrell SA. Comment on: Clinical benefits of ezetimibe: absence of proof is just that. Expert Opin Pharmacother 2013;14:2611-2
  • Gouni-Berthold I, Mikhailidis DP, Rizzo M. Author’s response. Expert Opin Pharmacother 2013;14:2612-3
  • Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92
  • Kohno T. Report of the American Heart Association (AHA) Scientific Sessions 2014, Chicago. Circ J 2014;79(1):34-40
  • Stitziel NO, Won HH, Morrison AC, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014;371:2072-82
  • Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314-24
  • Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011;9:533-71

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.